Exclusive: ACR Convergence 2024 | Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Conditions
FocusRheum
Guidance
Drug Updates
- Analgesics
- Biologics/DMARDs
Practice Support
- Billing/Coding
- EMRs
- Facility
- Insurance
- QA/QI
- Technology
- Workforce
Opinion
Career
ACR
Search

Th17 May Contribute to Bone Destruction by Modifying Osteoclasts

Lara C. Pullen, PhD | June 3, 2013

Page: 1 2 | Single Page

Share:

Filed under:Conditions Osteoarthritis and Bone Disorders Research Rheum Tagged with:Bone Destruction Osteoclasts Th17

Related Articles

A Duet of Bone and the Immune System

July 12, 2011

Examining emerging perspectives in osteoimmunology

New Treatments Needed to Prevent Fractures in Osteoporosis

June 1, 2014

Current therapies target pathways of bone remodeling, but rheumatologists say a better understanding of the mechanisms of bone resorption, formation is needed to make an impact

Methotrexate May Mitigate Inflammatory Bone Disease Note Experts at the ACR/ARHP Winter Rheumatology Symposium

April 2, 2014

By regulating molecules key to osteoclast/osteoblast processes, methotrexate may reduce bone destruction in inflammatory arthritis, osteolysis, especially in combination with adenosine

Osteoimmunology Research May Benefit Patients with Rheumatoid Arthritis

January 1, 2015

Cross-talk between bone biology, immune system may shed light on joint erosion, refine therapeutic targets for RA

About Us
Meet the Editors
Issue Archives
Contribute
Advertise
Contact Us

Copyright © 2000-2024 American College of Rheumatology. All rights reserved. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
DEI Statement
Privacy Policy
Terms of Use
Cookie Preferences